Resistant hypertension: Who and how to evaluate

Current Opinion in Cardiology

Volumn 24, Issue 4, 2009, Pages 340-344

  Acelajado, Maria Czarina ^a   Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Aldosterone; Diagnosis; Obstructive sleep apnea; Resistant hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ALDOSTERONE ANTAGONIST; AMPHETAMINE; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; COCAINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DECONGESTIVE AGENT; EPHEDRA SINICA EXTRACT; EPHEDRINE; FLUDROCORTISONE; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE; ALDOSTERONE;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG POTENCY; ENDOCRINE SURGERY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; PRIORITY JOURNAL; RESISTANT HYPERTENSION; REVIEW; SLEEP APNEA SYNDROME; TREATMENT RESPONSE; PROGNOSIS; RISK FACTOR; SLEEP DISORDERED BREATHING; TREATMENT FAILURE;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; PROGNOSIS; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; TREATMENT FAILURE;

EID: 67651174446     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32832bc6b5     Document Type: Review

References (20)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252. (Pubitemid 37553153)
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
3. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
4. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
5. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419. The American Heart Association recognized that resistant hypertension is a common clinical problem and summarizes what is known about the disease and makes empiric recommendations on its management based on limited research data.
6. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008; 168:2340-2346. This was the first study that recruited a large sample of patients with resistant hypertension and evaluated them prospectively for cardiovascular events. Prior studies had recruited patients with just essential hypertension (most of whom were not 'resistant').
7. Muxfeldt ES, Salles GF. Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension? J Hypertens 2008; 26:878-884. This study evaluated the relationship of TOD in patients with resistant hypertension with two parameters derived from ABPM. Limitations of this study include a crosssectional design and the use of surrogate end-points to assess cardiovascular risk.
8. Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892-896. (Pubitemid 35434912)
9. Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22:2217-2226. (Pubitemid 39463817)
10. Mosso L, Carvajal C, González A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42:161-165.
11. Gordon RD, Stowasser M, Tunny TJ, et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21:315-318. (Pubitemid 24201225)
12. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371:1921-1926. This study examined 20-year data from a hypertension clinic and found that the prevalence of primary hyperaldosteronism was 11.3% in their sample. This is much lower than the figures reported by other authors. (Pubitemid 351778191)
13. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:3266-3281. Management guidelines issued by The Endocrine Society for patients with primary aldosteronism. This study summarized key principles in screening, diagnosis and treatment and provided strength of evidence for each recommendation.
14. NishizakaMK,ZamanMA,CalhounDA.Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-930.
15. Chapman N, Dobson J, Wilson S. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839-845. (Pubitemid 351664214)
16. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens 2001; 19:2271-2277. (Pubitemid 33135251)
17. Goncalves SC, Martinez D, Gus M, et al. Obstructive sleep apnea and resistant hypertension. Chest 2007; 132:1858-1862.
18. Gus M, Goncalves SC, Martinez D. Risk for obstructive sleep apnea by Berlin questionnaire, but not daytime sleepiness, is associated with resistant hypertension: a case-control study. Am J Hypertens 2008; 21:832-835. This study found a strong association between OSA as predicted by the Berlin questionnaire and resistant hypertension, and confirmed OSA diagnosis by the use of a portable home monitor, instead of polysomnography. This may be a useful tool to screen for OSA in patients with resistant hypertension in which access to polysomnography may be limited. (Pubitemid 351913620)
19. Muiesan ML, Salvetti M, Paini A, et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52:529-534. This study measured left ventricular mass using echocardiography and found that patients with excess aldosterone had inappropriately increased left ventricular mass, ostensibly putting them at high risk for the development of decompensated LVH and heart failure.
20. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80-85. This study followed up patients who had undergone surgical or medical management to treat hyperaldosteronism and found that the risk for cardiovascular events decreased with treatment.